# 30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks

Study · id `cardio:ct-nct01183013` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01183013](<https://clinicaltrials.gov/study/NCT01183013>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01183013

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 936 participants.

## Technical summary

Registry record NCT01183013. Randomized; double masking; primary purpose treatment. Start 2010-08 (registry gives no type); primary completion 2013-02 (actual). Results posted on 2014-04-21.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 936 participants (enrolled count; ClinicalTrials.gov record NCT01183013, source copy `cardio:ctgov-nct01183013-2014-10-20`, retrieved 2026-10-26)
- Start date: 2010-08 (registry gives no type) (ClinicalTrials.gov record NCT01183013, source copy `cardio:ctgov-nct01183013-2014-10-20`, retrieved 2026-10-26)
- Primary completion: 2013-02 (actual) (ClinicalTrials.gov record NCT01183013, source copy `cardio:ctgov-nct01183013-2014-10-20`, retrieved 2026-10-26)
- Completion: 2013-02 (actual) (ClinicalTrials.gov record NCT01183013, source copy `cardio:ctgov-nct01183013-2014-10-20`, retrieved 2026-10-26)
- Results first posted: 2014-04-21 (ClinicalTrials.gov record NCT01183013, source copy `cardio:ctgov-nct01183013-2014-10-20`, retrieved 2026-10-26)
- Countries: United States; Estonia; Germany; Latvia; Spain; United Kingdom (ClinicalTrials.gov record NCT01183013, source copy `cardio:ctgov-nct01183013-2014-10-20`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01183013-2014-10-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: 30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Pioglitazone 15 mg
- Intervention (Drug): Pioglitazone 45 mg
- Intervention (Drug): Pioglitazone 30 mg
- Intervention (Drug): Linagliptin 5mg / Pioglitazone 45 mg FDC
- Intervention (Drug): Linagliptin 5mg / Pioglitazone 30 mg FDC
- Intervention (Drug): Linagliptin 5mg
- Intervention (Drug): Linagliptin 5mg / Pioglitazone 15 mg FDC
- Lead sponsor: Boehringer Ingelheim
- Lead sponsor class: INDUSTRY
- Collaborator: Eli Lilly and Company
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Boehringer Ingelheim (`cardio:boehringer-ingelheim`)
- Registry lists this organization as a collaborator: Eli Lilly and Company (`cardio:eli-lilly`)

## Provenance

Content hash: e52aa85c23f9864ab767695534bf68ca48d02e0c4204ad8546b2abe6da2027d1
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
